Sangamo Biosciences reported $336.62M in Current Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Alnylam Pharmaceuticals ALNY:US USD 2.69B 219.21M
Amgen AMGN:US USD 22.19B 1.88B
Avrobio Inc AVRO:US USD 126.23M 15.85M
Bayer BAYN:GR EUR 38.41B 1.14B
Biogen BIIB:US USD 9.77B 24.9M
Biomarin Pharmaceutical BMRN:US USD 2.68B 165.1M
Bluebird Bio BLUE:US USD 160.44M 7.02M
Gilead Sciences GILD:US USD 15.23B 1.67B
GlaxoSmithKline GSK:LN GBP 20.77B 520M
Intercept Pharmaceuticals ICPT:US USD 545.37M 58.36M
IONIS PHARMACEUT IONS:US USD 2.15B 39.02M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Novartis NOVN:VX USD 36.95B 1.19B
Omeros OMER:US USD 288.54M 95.82M
Regulus Therapeutics RGLS:US USD 49.37M 2.02M
Roche Holding ROG:VX 30.32B 5.31B
Sangamo Biosciences SGMO:US USD 336.62M 6.5M
Sarepta Therapeutics SRPT:US USD 2.63B 156.63M
Ultragenyx Pharmaceutical RARE:US USD 1.01B 334.13M
Vertex Pharmaceuticals VRTX:US USD 12.27B 767.5M
Ziopharm Oncology ZIOP:US USD 55.5M 5.86M